DocumentsDate added
Original article:-
Laila Mahmoud Matalqah*1,2 , Khaldoon Mahmoud Radaideh3 , Syed Azhar Syed Sulaiman1 , Mohamed Azmi Hassali4 & Muhamad Ali Sk Abdul Kader5
Affiliation:-
Laila Mahmoud Matalaqah (M.Pharm, clinical pharmacy) PhD Candidate, 1Displine of Clinical Pharmacy, School of Pharmaceutical sciences, Universiti Sains Malaysia (USM),2School of Pharmacy, Allianze University College of Medical Sciences (AUCMS), Kepala Batas, Malaysia. Dr. Khaldoon Mahmoud Radaideh (PhD), School of Medical Imaging and Radiotherapy, 3Allianze University College of Medical Sciences (AUCMS), Kepala Batas, Malaysia Prof. Dr. Syed Azhar Syed Sulaiman, PhD. Clinical Pharmacy, 1Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences Universiti Sains Malaysia (USM), Penang, Malaysia. Assoc. Prof. Dr. Mohamed Azmi Ahmad Hassali (Ph.D. Clinical. Pharm), Deputy Dean (Student Affairs & Networking) 4School of Pharmaceutical Sciences, Universiti Sains Malaysi a (USM), Penang, Malaysia. Dr. Muhamad Ali Sk Abdul Kader, MD (USM) MRCP (UK) CMIA FACC (USA)FNHAM, Consultant 5Cardiologist, Department Of Cardiology, Penang Hospital, Malaysia.
Abstract:- Objective: To relate the level of patients’ knowledge about warfarin to their anticoagulation control using a translated Malaysian version of Oral Anticoagulation Knowledge (OAK) Test. Methods: A prospective, cross-sectional study design and methodology were used to elaborate the study data. 382 consecutive outpatients with atrial fibrillation undergoing oral anticoagulant were identified between September 2011 and January 2013 at Hospital Pulau Pinang and Seberang Jaya Hospital, Penang, Malaysia. A standard translation procedure was used to develop the Malaysian version of the 20- question-OAK test from the original English version. Medical records were reviewed for INR levels and other clinical data. To determine the correlation between INR control and warfarin knowledge, spearman correlation analysis was used. Significant was defined as P <0.05. Results: Only 215 were eligible and accepted to complete the questionnaires. The mean±SD of OAK scores was 47.6±17.6. Good internal consistency was found (Cronbach’s alpha = 0.767); and the test-retest reliability value was 0.871 (p<0.001). Data from the Spearman’s rho analyses revealed a statistically significant positive but weak correlation between patients’ knowledge and the number of INR values that were within the therapeutic range Conclusion: A significant relationship between OAK categories and TTR (INR) categories (p <0.05) was found. The Malaysian version of the OAK had a moderate sensitivity and specificity, 58.3% and 58.0%, respectively, with good predictive validity.
Key Words:- anticoagulation, warfarin, patient knowledge, Malaysian version.
References:
1.Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns J A, Joyner C. Canadian Atrial Fibrillation Anticoagulation Study. J Am Coll Cardiol 1991; 18:349-55.
2.Ezekowitz MD, Bridgers SL, James KE. et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
3.Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–67.
4.Faridah AMY, Sivasampu S, Lian LM, Hazimah H, Kok LC, & Chinniah RJ. Malaysian Statistics on Medicine 2007. A publication of the Pharmaceutical Services Division and the Clinical Research Centre, The National Medicines Use Survey, Ministry of Health Malaysia, 2010.
5.Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest 2008; 133:160S-198S.
6.Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095-1106.
7.Greenblatt DJ, & von Moltke LL. Interaction of warfarin with drugs, natural substances and foods. JClin Pharmacol 2005;45:127-32.
8.Taylor FC, Ramsay ME, Tan G, Gabbay J, Cohen H. Evaluation of patients knowledge about anticoagulation treatment. Qual Health Care 1994;3(2):7985.
9.Barcellona D, Contu P, Marongiu F. Patient education and oral anticoagulation therapy. Haematologica 2002; 87(10):1081-86.
10.Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of Anticoagulation Therapy in Well-informed Older Patients. Arch Intern Med 2004; 164:2044-50.
11.Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004; 126:557-64.
12.Zeolla MM, Brodeur MR, Dominelli A, Haines ST, Allie ND. Development and validation of an instrument to determine patient knowledge: the oral anticoagulation knowledge test. Ann Pharmacother 2006;40(4):633-8.
13.Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother 2003;37:34-9.
14.Barcellona D, Contu P, Marongiu F. A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control. J Thromb Thrombolysis 2006; 22:185-90.
15.Jank S, Bertsche T, Herzog W, Haefeli WE. Patient knowledge on oral anticoagulants: results of a questionnaire survey in Germany and comparison with the literature. Int J Pharmacol Ther 2008; 46(6):280-8.
16.Roche-Nagle G, Chambers F, Nanra J, et al. Evaluation of patient knowledge regarding oral anticoagulants. Ir Med J 2003; 96(7): 211-3.
17.McCabe PJ, Schad S, Hampton A, Holland DE. Knowledge and self-management behaviors of patients with recently detected atrial fibrillation. Heart Lung 2008;37(2):79-90.
18.Pernod G, Labarère J, Yver J, et al. EDUC’AVK: Reduction of Oral Anticoagulant-related Adverse Events after Patient Education: A Prospective Multicenter Open Randomized Study. J Gen Intern Med 2008; 23(9):1141-6.
19. Hasan SS, Shamala R, Syed IA. et al. Factors Affecting Warfarin-Related Knowledge and INR Control of Patients Attending Physician- and Pharmacist Managed Anticoagulation Clinics. J Pharm Prac 2011.DOI: 10.1177/0897190011415684.
20.Yahaya AHM, Hassali MA, Awaisu A, Shafie AA. Factors associated with warfarin therapy knowledge and anticoagulation control among patients attending a warfarin clinic in Malaysia. J Clin Diag Res 2009; 3:1663-70
21.Devellis RF. Scale development: theory and applications. Newbury Park, CA: Sage Publications, 1991. 22.Kline P. A handbook of test construction: introduction to psychometric design. New York: Methuen & Co, 1986.
23.Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. New York: Oxford University Press, 1989.
24.Briggs AL, Jackson TR, Bruce S, Shapiro NL. The development and performance validation of a tool to assess patient anticoagulation knowledge. Res Social Adm Pharm 2005;1(1):40-59.
25.Winans AR, Rudd KM, Triller D. Assessing anticoagulation knowledge in patients new to warfarin therapy. Ann Pharmacother 2010; 44(7-8):1152-7.
26.Khudair IF, Hanssens YI. Evaluation of patients’ knowledge on warfarin in outpatient anticoagulation clinics in a teaching hospital in Qatar. Saudi Med J 2010; 31(6)672-7.
27.Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health- related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993; 46:1417-32.
28.Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005;8: 94-104
29.ACCF/AHA/HRS Guideline. Management of Patients with Atrial Fibrillation. Circulation 2011;123:104–23 and 1161–7.
30.Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69:236-9.
31.Connolly SJ, Pogue J, Eikelboom J, Flaker G. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029-37.
32.Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with nonvalvar atrial fibrillation: A record linkage study in a large British population. Heart 2005; 91:472–7.
33.Veeger NJ, Piersma-Wichers M, Tijssen JGP, Hillege HL, Meer J. Individual time within target range in patients treated with Vitamin K antagonists: Main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128:513-19.
34.White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007; 167:239-45.
35.Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Joint Commission on Accreditation of Healthcare Organizations 2009;35(3):146-55
36.Nunnally JC, Bernstien IH. Psychometric Theory, 3rd ed. New York: McGraw-Hill, 1994.
37. Hu A, Chow C, Dao D, Errett L, Keith M. Factors Influencing Patient Knowledge of Warfarin Therapy After Mechanical Heart Valve Replacement. J Cardiovascular Nurs 2006; 21(3):169-75.
38.Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of Adherence, Knowledge, and Quality of Life on Anticoagulation Control. Ann Pharmacother 2005;39:632-6.
39.The Newcastle Anticoagulation Study Group (Group TNAS). Effectiveness of anticoagulation among patients discharged from hospital on warfarin. MJA 1998; 169:243-46.
40.Smith MB, Christensen N, Wang S, et al. Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. Cardiology 2010; 116:61-9.
41.McCormack PM, Stinson JC, Hemeryck L, Feely J. Audit of an anticoagulant clinic: doctor and patient knowledge. Ir Med J 1997; 90(5):192-3.
42.Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients' perspectives on taking warfarin: qualitative study in family Practice BMC. Fam Pract 2004;5(15).
43.Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: Effects of an educational intervention programme. Int J Cardiol 2006; 110:354-8.
44.St-Louis L, Robichaud-Ekstrand S. Knowledge level and coping strategies according to coagulation levels in older persons with atrial fibrillation. Nurs Health Sci 2003; 5:67-75.
45.Cheah GM, Martens KH. Coumadin Knowledge Deficits: Do Recently Hospitalized Patients Know How to Safely Manage the Medication? Home Healthc Nurse 2003;21(2):94-100.
46.Baker WJ, Pierce KL, & Ryals CA. INR goal attainment and oral anticoagulation knowledge of patients enrolled in an anticoagulation clinic in a Veterans Affairs Medical Center. J Manag Care Pharm 2011,17 (2),133-42.
47.Fang MC, Machtinger EL, Wang F, & Schillinger D. Health literacy and anti- coagulation-related outcomes among patients taking warfarin. J Gen Inter Med, 2006, 21(8), 841-6.
*Correspondence address:
Laila Mahmoud Ali Matalqah.,
Displine of Clinical Pharmacy,
School of Pharmaceutical Sciences, Minden, 11800, Universiti Sains Malaysia (USM),Malaysia.
lmatalqah@yahoo.com, lailamatalqah@allianzeunicollege.edu.my
Telephone:-0060175029392
Research article:-
Soumendra Sahoo1* & Padma Lochan.Nayak 2
1 Melaka Manipal Medical College, Melaka, Malaysia.
2 P.L.Nayak Research Foundation, Centre for Nanoscience and Technology, Synergy Institute of Technology, Bhubaneswar, Odisha ,India.
Abstract:- Chitosan-Gelatin/montmorillonite Cloisite 30 B (MMT) hybrid nanocomposites were prepared by blending chitosan-Gelatin with Cloisite 30B in aqueous solution. The nano composites were characterized by using FTIR, SEM and XRD analysis. From the FTIR spectra the various groups present in the chitosan-Gelatin blend were monitored. The homogeneity, morphology and crystallinity of the blends were ascertained from SEM and XRD data, respectively. The results indicated that an intercalated or partially exfoliated nanocomposite could be achieved, and the properties of the composite were significantly improved. The drug release kinetics was investigated using ketorolac as the drug. The kinetics of the drug delivery system has been systematically studied. Drug release kinetics was analyzed by plotting the cumulative release data vs. time by fitting to an exponential equation which indicated the non-Fickian type of kinetics. The drug release was investigated at different pH medium and it was found that the drug release depends upon the pH medium as well as the nature of matrix.
Key Words:- Chitosan,Gelatin, Cloisite 30 B, Ketorolac, Drug delivery, Kinetics.
References:-
1.Smart, J. D. The basics and underlying mechanisms of mucoadhesion. Adv.Drug Del. Rev.2005;57(11):1556-68.
2.Hägerström, H.; Edsman, K.; Strømme, M. Low- Frequency Dielectric Spectroscopy as a Tool for Studying the Compatibility between Pharmaceutical Gels and Mucus Tissue. J. Pharm. Sci.2003;92(9):1869-81.
3.Woodley, J. Bioadhesion, new possibilities for drug administration? Clin. Pharmacokinet.2001;40(2):77-84.
4.Andrews, G. P.; Laverty, T. P.; Jones, D. S. Mucoadhesive polymeric platforms for controlled drug delivery, Eur. J. Pharm. Biopharm.2008;71(3):505-18.
5.Sahoo Debashish., Sahoo sarmila., Mohanty P.,Sasmal S and Nayak P.L Chitosan: a new versatile biopolymer for various applications.J.designed monomer and polymer. 2009; 12:377-404.
6. Sahoo Debashish. and Nayak P.L.Release Behaviour of Chloramphenicol From N-Acyl Derivatives of Chitosan. NanoTrends: A Journal of Nanotechnology and Its Applications, 2012; 1:01-09.
7.Malesu V. K., Sahoo Debashish. and Nayak P.L. Chitosan–Sodium Alginate Nanocomposites Blended with Cloisite 30B As a Novel Drug Delivery System for Anticancer Drug Curcumin , International Journal of Applied biology and Pharmaceutical Technology.2011;2(3):402-11.
8.Sahoo Debashish. and Nayak P.L. Synthesis and Characterization of Chitosan Nanocomposite Film for controlled Release of Ofloxacin. Journal of Applied Polymer Science 2011;123(5):2588-94.
9.Nayak P.L. & Sahoo Debashish. Chitosan-alginate composites blended with cloisite 30B as a noveldrug delivery system for anticancer drug paclitaxel. International Journal of Plastics Technology.2011;15(1):68-81.
10.Sahoo Debashish., Sahoo sarmila., Das J., Dangar T.K., and Nayak P.L. Antibacterial Activity of Chitosan Cross Linked with Aldehydes and Blended with Cloisite 30 B.NanoTrends: A Journal of Nanotechnology and Its Applications 2011;10(2):1-9.
11.Sahoo Sarmila., Sasmal Abhisek., Sahoo Debashish., Nayak P.L.Synthesis and Characterization of Chitosan-Polycaprolactone Blended with Organoclay for Control Release of Doxycycline.Journal of Applied Polymer Science2010;118(6):3167-75 .
12.Book Chapter on Chitosan : Sahoo Debasish . and Nayak P.L., Chitosan: The Most Valuable Derivative of Chitin (Chapter 6) in Biopolymers: Biomedical and Environmental Application, (129–166), Scrivener Publishing LLC, (ISBN: 9780470639238 ).
13. Lee, J. W.; Park, J. H.; Robinson, J. R. Bioadhesive-based dosage forms: The next generation. J. Pharm. Sci 2000;89(7):850-66.
14.Nanda P K, Rao K K, Kar R K and Nayak P L,Biodegradable polymers: Part VI. Biodegradable plastics of soy protein isolate modified with thiourea. Journal of Thermal Analysis and Calorimetry 2007;89(3):935–40.
15. Draye J P, DelaeyB,Voorde A V D, Bulcke A V D, Reu B D,and Schacht E, Biomaterials1998;19:1677.
16.Maeda T, Motoyoshi and H. Jpn, J PolymSciTechnol 1996; 53:155.
17.Fakirov S, Sarac Z, Anbar T, Boz B, Bahar I, Evstatiev M, Apostolov A. A, Mark J. E and Kloczkowski A, Colloid PolymSci 1996; 274: 334.
18.Fakirov S, SaracZ, Anbar T, Boz B, BaharI,Evstatiev M, ApostolovA. A, MarkJ. E and Kloczkowski A, ColloidPolymSci 1997; 275: 307.
19.Zhao W Y, Kloczkowski A, Mark J. E, Erman Band Bahar I and Chemtech March.1996; 26:30.
20.BigiA,Panzavolta S, Roveri N, Biomaterials.1998;19:739.
21.Lin F H, Yao C. H and SunJ. S, Biomaterials.1998; 19: 905. 22.Wan Y. Z, Wang Y. L, Luo H. L,Cheng G. X and Yao K. D. J ApplPolymSci.2000; 75:987.
23.Andrade JR, Maslanka M, Maneatis T, Bynum L, Burchomore M. The use of Ketorolac tromethamine in the management of post operative pain. Orthopedics 1994; 17:157–66. PMid:8190679
24.Shankar C, Mishra M. Development and in-vitro evaluation of gelatin A microspheres of Ketorolac tromethamine for intranasal administration. Acta Pharm 2003; 53:101–10. PMid: 14764244
25.Shyamala B, Sanmathi BS. Poly(lactic acid) microspheres of Ketorolac tromethamine for parenteral controlled drug delivery system. Indian J Pharm Sci 2001; 63: 538–40.
26.Shyamala B, Sanmathi BS. Influence of manufacturing parameters and the release profile of Ketorolac tromethamine from poly (Lactide-co-glycolide) microspheres. Indian Drugs. 2001; 38: 383–5.
27.Kulkarni A.R., Soppimath K.S., and Aminabhavi T.M. Controlled Release of Diclofenac Sodium from Sodium Alginate Beads Crosslinked with Glutaraldehyde,” Phar- maceuticaActaHelvetiae 1999;74: 29-36. doi:10.1016/0168-3659(87)90035-6.
28.Vimala K., Mohan Y.M., Varaprasad K., Redd N.N., RavindraS.,Naidu N.S.,.Raju K.M., (2011).Fabrication of Cur- cumin Encapsulated Chitosan-PVA Silver Nanocompo- site Films for Improved Antimicrobial Activity,Journal of Biomaterials and Nanobiotechnology,2011;255-64 :doi:10.4236/jbnb.2011.21008.
29.Singla A.K., Garg A.and Aggarwal D. Paclitaxel and its formulations,” International Journal of Pharmaceutics, 2002;235(1):179-92. doi:10.1016/S0378-5173(01)00986-3 .
30.Singla A.K.and Chawla M.,(2001). Chitosan: Some Pharma-ceutical and Biological Aspects—an Update, Journal of Pharmacy and Pharmacology 2001; 53(8):1047-67. doi:10.1211/0022357011776441.
Copyright © 2013 Soumendra Sahoo & Padma L.Nayak. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
*Correspondence address:
Prof Dr Soumendra Sahoo.,
Head, Ophthalmology,
Melaka Manipal Medical College, Melaka 75150 Malaysia.
Case controlled study:- Biochemistry
Sharma Priyanka1, Prasad Suvarna 2 & Tangri Nitin 3*
1,2Department of Biochemistry, 3Department of Respiratory Medicine, MM Institute of Medical Sciences, Mullana, Ambala, Haryana– India.
Abstract:-
Background:-Infertility represents a common condition nowadays, with important medical, economic and psychological implications. Traditionally, measurement of Prolactin and thyroid hormones, especially thyroid stimulating hormone (TSH) has been considered an important component of infertility workup in women. Aims: - The study was designed to evaluate the status of thyroid function in female infertility after exclusion of tubal factor and male factor infertility, and to investigate the impact of thyroid status on serum Prolactin. Method:-In this retrospective case control study, we investigated fifty (50) infertile women in the age range of 20- 40 years attending department of Biochemistry, MMIMSR, Mullana (Ambala) for hormonal evaluation from November, 2010 to October, 2011. Fifty (50) fertile women with similar age range were selected as controls. The association between thyroid dysfunction and levels of serum Prolactin was reviewed. Results: - The majority of infertile and fertile women were euthyroid and there was no significant association between Infertility & TSH (p > 0.05). Hyperprolactinemia was depicted in 32% infertile women. Prevalence of primary infertility was 76% while that of secondary infertility cases was 24%. There was a negative correlation between serum TSH and Prolactin levels in infertile subjects (p < 0.05). Conclusion: - There was higher prevalence of hyperprolactinemia with normal thyroid function in infertile patients.
Keywords:- Thyroid Stimulating Hormone (TSH), Prolactin (PRL), Hyperprolactinemia, Infertility.
References:-
1.Poppe K, Velkeniers B. Thyroid and Infertility. Vertin K Acad Geneeskd Belg 2002; 64:389-99.
2.Frey KA, Patel KS. Initial evaluation and management of infertility by the primary care physicians. Mayo Clin Proc 2004; 79:1439-43.
3.Evaluation and Management of the infertile couple. 2008(accessed on 08 Feb, 2012) http://www.glowm.com/?p=glowm.cml/sectionview&articleid=320.
4.Indian Council for Medical Research (ICMR) and National Academy of Medical Sciences (NAMS). National Guidelines for Accreditation, Supervision and Regulation of ART clinics in India. New Delhi:Ministry of Health and Family Welfare, Government of India; 2005.
5.Hendershot GE, Mosher WD, Pratt WF. Infertility and age: An unresolved issue. Fam Plann Perspect 1982; 14:287.
6.Cramer DW, Sluss PM, Powers RD,McShane P, Ginsburgs ES, Hornstein MD et al.Serum Prolactin and TSH in an invitro fertilization population: is there a link between fertilization and thyroid function? J Assist Reprod Genet 2003; 20(6):210-5.
7.Poppe K, Velkeniers B. Thyroid disorders in infertile women. Ann Endocrinol (Paris) 2003; 64(1):45-50.
8.Donfas AG, Mastorakos G. The hypothalamic-pituitary-thyroid axis and the female reproductive system. Ann N Y Acad Sci.2000; 900:65-76.
9.Poppe K, Velkeniers B, Glinoer D. Thyroid disease and female reproduction. Clin Endocrinol (Oxf) 2007; 66(3): 309-21. Review
10.Zollner U, Lanig K, Steck T, Dietl J. Assessment of Endocrine status in patients undergoing in-vitro fertilization treatment. Is it necessary? Arch Gynecol Obstet 2001; 265(1): 16-20.
11.Mishra R, Baveja R, Gupta V. Prolactin levels in infertility with menstrual irregularities. J Obstet Gynecol India 2002; 52:40-3.
12.Del Pozo E, Wyss H, Tollis G, Alcaniz J, Campana A, Naftolin F. Prolactin and deficient luteal function.Obstet Gynecol.1979;53(3):282-6.
13.Wakim AN, Polizotto SL, Burholt DR. Inflence of thyroxine on human granulosa cell steroidogenesis in vitro. J Assist Reprod Genet.1995; 12(4):274-7.
14.Binita G, Suprava P, Mainak C, Koner BC, Alpana S. Correlation of Prolactin and Thyroid hormone concentration with menstrual patterns in Infertile women. J Reprod Infertil.2009; 10:207-12.
15.Kumkum A, Jasmine K, Shweta G, Pal Ajeshwar N. Hyperprolactinemia and its correlation with hypothyroidism in infertile women. J Obstet Gynecol India.2006; 56(1): 68-71.
16.Freeman ME, Kanyiscka B, Lerant A, Nagy G. Prolactin:Structure, Function and Regulation of Secretion. Physiol Rev.2000; 80:1523-1631.
17.Litwack G, Schmidt TJ. Biochemistry of hormones 1: Polypeptide hormones. In: Devlin TM, editor. Textbook of biochemistry with chemical correlation. 5th edition New York: Wiley – Liss; 2002. pp 906 – 957.
18.Park K. Nutrition and health. In : Park’s textbook of preventive and social medicine. 19th edition. India : M/S Banarsidas Bhanot publishers ; 2007. pp 480 – 533.
19.Hendershot GE, Mosher WD, Pratt WF. Infertility and age : an unresolved issue. Fam Plann Perspect 1982; 14: 287. 20.Zimmermann MB. Iodine deficiency. Endocrine Reviews 2009; 30 (4) : 376 – 408.
21.Freeman ME. The neuroendocrine control of the ovarian cycle of rat. The physiology reproduction 1994: 613 – 58.
22.Rothchild I. The regulation of mammalian corpus luteum. Rec Prog Horm Res. 1994; 37: 183 – 298.
Copyright © 2013 Sharma Priyanka, Prasad Suvarna & Tangri Nitin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
*Correspondence address:
Dr. Nitin Tangri,
Department of Respiratory Medicine,
MM Institute of Medical Sciences, Mullana, Ambala ,Haryana – India.
Contact no:-+91-9729456330.
Short communication:-
Vela Desai1, Prena Pratik1* & Rajeev Sharma1**
Affiliation:-
1Prof & HOD, 1*PG Student,1**Senior Lecturer, Department of Oral medicine and radiology(OMR),Jaipur Dental College,Dhand, Amet, Thesil,Jaipur, Rajasthan, India.
Abstract :-
Recently, “Ergonomics” is being frequently used in the profession of dentistry. Good ergonomics is essential so that work capability, efficiency and high clinical level of treatment can be maintained throughout the working life of dental professionals. The scope of ergonomics in dentistry is large. Dentistry has always been known as an uneasy occupation therefore one must take into account the serious health hazards faced by the dentists. When talking about the musculoskeletal disorders it might be assumed that the knowledge of ergonomics may be of some use.
Key Words:- Ergonomics, dentists.
References:-
1.Pekka Kahri.Ergonomics and teamwork in dental treatment.PLANMECA OY 2005;1:1.
2.P. BUCKLE: ERGONOMICS AND MUSCULOSKELETAL DISORDERS,Occupational Medicine 2005;55:166.doi:10.1093/occmed/kqi081.
3.en.wikipedia.org[updated on 22 April 2013;cited on 2013 April 25 ]. Available from http://en.wikipedia.org/wiki/Systems_psychology.
4.Gupta S. Ergonomic applications to dental practice. Indian J Dent Res 2011;22:816-22.
5.Hill KB, Burke FJ, Brown J, Macdonald EB, Morris AJ, White DA, Murray K. Dental practioners and ill health retirement: A qualitative investigation into the causes and effects. Br Dent J 2010;209: E8.
6.R. Nutalapati, R. Gaddipati, H. Chitta, M. Pinninti, R. Boyapati: Ergonomics in Dentistry and the Prevention of Musculoskeletal Disorders in Dentists. The Internet Journal of Occupational Health. 2010 Volume 1 Number 1. DOI: 10.5580/c9b.
7.Occupational Safety and Health Administration, 29 CFR Part 1910. [Docket No. S-777],RIN No. 1218-AB36.[updated on November 14, 2000;cited on 24 April 2013]. Available from http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=federal_register&p_id=16305.
8.Third age. com[cited on 2013 April 25].Available from http://www.thirdage.com/hc/g/musculoskeletal-disorder-symptoms.
9.James B. Bramson, Scott Smith, Guido Romagnoli. Evaluating Dental Office Ergonomic Risk Factors And Hazards. J Am Dent Assoc 1998;129:174-183.
10.Technical Profile. Dental Operating Microscopes: Don’t Equip an Operatory Without One. Inside Dentistry 2007;5:2-4.
11.Public Services Health & Safety Association[updated on 30 April 2013;cited on 2013 January 25].Available from http://www.healthandsafetyontario.ca/HSO/ media/ PSHSA/ pdfS/ MSDs/MSDs.pdf.
12.INDIAN HEALTH SERVICE.ERGONOMICS RECOMMENDATIONS FOR DENTAL PROGRAMS [cited on 2013 Januruary 17]. Available from http://www.dentalclinicmanual.com/docs/Ergonomic_considerations.pdf.
13.Dr.Michael Dougherty. Ergonomics principles in dental setting: part 1[Cited on 2012 Janurary 13] Available from http://www.eugenol.com/attachments/0007/6874/papers_ergonomic_principles_part1.pdf.
14.Ergonomics and dental work. Occupational Health Clinics for Ontario Workers Inc. Available from http://www.ohcow.on.ca/uploads/Resource/Workbooks/ ERGONOMICS %20AND%20DENTAL%20WORK.pdf.
15.Selecting Ergonomically Sound Equipment. OSHA Program Manual for Dental Facilities.[Cited on 2013 Feb 12 ]Available from http://blogs.hcpro.com/osha/wp-content/uploads/2011/07/DOSPM2_7-8.pdf.
16.Priyanka Airen Sarkar, Anand L Shig. Ergonomics in General Dental Practice.People’s Journal of Scientific Research 2012 Jan;5(1):60.
*Correspondence address:
Dr.Prena Pratik,
PG Student,
Department of Oral medicine and radiology(OMR),
Jaipur Dental College, Dhand, Amet, Thesil, Jaipur, Rajasthan, India.
Copyright © 2013 Vela Desai,Prena Pratik & Rajeev Sharma. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:- Microbiology
T. Karuna1*, K.Vishnuvardhana Rao2,P.Ratna Kumari3 & K. Prabha Devi3**
Affiliation:- *1Department of Microbiology Hi-Tech Medical college & hospital ; Block 3,flat 1,Pandara Rasulgarh, Bhubaneswar ,Odisha, India. 2Associate professor, Department of Microbiology, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences, Chinoutapally, Gannavaram, Krishna Dist. Andhra Pradesh, India. 3Associate Professor, Department of Microbiology, 3**Professor and Head of the Department of Obstetrics and Gynaecology,Siddhartha Medical college and hospital , Vijayawada, Andhra Pradesh, India.
Abstract:- Background: India is a developing country with large population of child bearing age group, majority from low socioeconomic status. Unaware of the possibilities of asymptomatic bacteriuria and its complications and often neglecting minor symptoms due to ignorance, lack of medical facilities; ultimately face antenatal, perinatal and postnatal complications. So present study was taken up at Siddhartha medical college & hospital Vijayawada, Andhra pradesh to know the prevalence of symptomatic and asymptomatic bacteriuria in antenatal women. Material & Methods: We conducted a prospective observational type of hospital based study. A predesigned proforma to take detailed history was designed. Midstream urine samples collected from 500 pregnant women were transported and processed within 1 h. The urine specimens were first tested by screening methods and then processed by quantitative and semiquantitative culture methods. Results: 4.5% symptomatic cases and 9.3% asymptomatic cases showed culture positive bacteriuria. Gram Stain was most sensitive and specific screening method compared with semiquantitative standard loop culture method. Escherichia coli was the most common organism isolated;( 78.5%) in asymptomatic bacteriuria and (66.6%) in symptomatic bacteriuria patients. Nitrofurantoin was the most sensitive drug (77.5%), followed by Cephalexin (67.5%). Prenatal and postnatal complications were more common in noncomplaint asymptomatic bacteriuria patients. Conclusion: All pregnant women should be screened by urine culture, from 1st trimester continuing throughout pregnancy irrespective of socioeconomic status, parity and age. Most antenatal, postnatal and perinatal complications can be prevented by routine screening and treatment.
Key Words:- Antenatal women, Asymptomatic bacteriuria(ASB), Symptomatic bacteriuria(SB).
References:-
1. Lavanya S.V. et al, Asymptomatic bacteriuria in antenatal women,Indian Journal of Medical Microbiology 2002; 2 (20):105-6.
2. Patton JP, Nash DB, Abrutyn E: Urinary tract infection: Economic Consideration, Med. Clin. North Am 1991; 75:495.
3. Mc LaughlinS P, Carson CC, Urinary tract infections in women Medical Clinics of North America, 2004; 88(2):417-29.
4. Kass EH, Pyelonephritis and Bacteriuria: a major problem in preventive medicine. Ann. Int. Med 1962; 56:46-53.
5. Laura A, Schieve, MS, et al Urinary Tract Infection during Pregnancy: It’s association with Maternal Morbidity and Perinatal Outcome. American Journal of Public Health, 1994; 84(3): 405- 10.
6. Gilstrap L.C., 3rd, Ramin S.M. Urinary Tract Infections during Pregnancy, Obstetrics Gynaecology, Clinic of North America 2001; 28(3): 581-91.
7. Mandell G.L., Bennett J.E., et.al. part I, section B, urinary tract infections chapter 66, principles and practice of infectious diseases, 6th edition, volume I, p 875 – 900.
8. F.Gary Cunningham, M.D., et.al.section XII medical and surgical complications in pregnancy, chapter 47, renal and urinary tract disorders, section II, physiology of pregenancy, chaper 8. Maternal adaptation to pregnancy. Williams obstetrics 21 edition, P 1253 – 1258, 186-188, Mc Graw – Hill publisher. 9. Patterson TF, Andriole VT, Detection, Significance and Therapy of Bacteriuria in Pregnancy, Update in the Managed Health care era, Infectious disease Clin. North America 1997; 11(3)593-608.
10. Betty A.forbes, Daniel F.Sahm, et.al, Part –VII diagnosis by organ system, chapter -57, infection of the urinary tract, Bailey and scott’s diagnostic microbiology, 12th edition P 842,855.
11. Mosby publishers. Baron E J, Peterson L R, Finegold S M. Bailey and Scott’s diagnostic microbiology. 9th ed. St. Louis, Mo: Mosby; 1994. pp. 249–257.
12. Hooton TM, Scholees D, Stapleton AE, et al. A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med 2000; 343:992–7.
13.Macejko A.M. et al. Asymptomatic Bacteriuria and symptomatic urinary tract infections during pregnancy; Urologic Clin. N. Am. 34(2007):35-42.
14. Connolly AM et al. Urinary tract infections in pregnancy, Urologic Clinics of North America 1999; 26(4): 779-87.
15. Kutlays et al. Prevalence, detection and treatment of asymptomatic bacteriuria in a Turkish obstetric population, J. Reprod. Med 2003 Aug; 48(8): 627-30. 16. Khattak AM et al. Pakistan Journal of Med. Sci., 2006 ;22(2):162-6.
17. Hanif S, Dept. of Obst & Gynaecology, Fatima Memorial Hospital Collge, Lahore, JCPSP 2006;16(8); 514-7.
18. Bandhopadhyay S, Thakur et al. High prevalence of bacteriuria in pregnancy and its screening methods in north India, Journal Indian Med. Assoc. 2005 May; 103(5): 259-62, 66.
19.Collee J.G.,FraserA.G, et.al. , Laboratory strategy in the diagnosis of infective syndromes,section 11, urinary tract infections chapter 4,Mackie &McCartney practical medical microbiology, 14th edition, p 89 – 90.
20.Mc Fadyer SJ et al. Incidence of asymptomatic Bacteriuria in Primis, The Jour of Obst Gyne of Brit Common Wealth 1973; 5: 80.
21.Jai Bhagawan Sharma, Suneeth Sharma et al. Prevalence of Significant Bacteriuria in Preterm Labour; Jour. Obst.Gyn. Of India 1990; 40(3):336-8.
22. Schieve LA, Handler A, Hershow R, et al. Urinary tract infection during pregnancy: Its association with maternal morbidity and perinatal outcome. Am. J. Public Health, 1994; 84: 405-41.
23. Ian Donald-Practical Obst. Problems, P. 273-77, 1974, PG Publishing Pvt. Ltd., (Publishers).
24. Kincaid-Smith P, Buller M, Bacteriuria in Pregnancy, Lancet 1965; 1: 395-9.
25. F.Gary Cunningham, M.D., et.al.section XII medical and surgical complications in pregnancy, chapter 47, renal and urinary tract disorders, section II, physiology of pregenancy, chaper 8.Maternal adaptation to pregnancy.Williams obstetrics 21 edition, P 1253 –1258, 186-188, Mc Graw – Hill publisher.
26. Eshwarappa M, Dosegowda R, Aprameya IV, Khan MW,Kumar PS, Kempegowda P. Clinico-microbiological profile of urinary tract infection in south India. Indian J Nephrol 2011; 21(1):30-6.
27. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002; 287(20):2701-10.
28. Guinto VT, De Guia B, Festin MR, Dowswell T. Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD007855. DOI: 10.1002/14651858.CD007855.pub2.
29. Vazquez JC, Abalos E. Treatments for symptomatic urinary tract infections during pregnancy. CochraneDatabase of Systematic Reviews 2011, Issue 1. Art. No.: CD002256. DOI: 10.1002/14651858.CD002256.pub2.
*Correspondence address:
Dr. T. KARUNA,
M.D. Microbiology, Assistant professor Department of Microbiology,
Hi-Tech Medical college & hospital; Block 3, flat 1, Pandara, Rasulgarh,
Bhubaneswar, Odisha, India;
Contact no: +91-9437373359.
Copyright © 2013 Mitul Kumar Mishra & Shilpi Tiwari. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.